Bicara Therapeutics Inc.
BCAX
$11.32
-$0.52-4.39%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -3.15% | 10.38% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -23.38% | 56.88% | |||
| Operating Income | 23.38% | -56.88% | |||
| Income Before Tax | 25.66% | -77.04% | |||
| Income Tax Expenses | -27.78% | -61.29% | |||
| Earnings from Continuing Operations | 25.67% | -75.82% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 25.67% | -75.82% | |||
| EBIT | 23.38% | -56.88% | |||
| EBITDA | 23.39% | -56.90% | |||
| EPS Basic | 25.78% | -75.69% | |||
| Normalized Basic EPS | 25.78% | -76.98% | |||
| EPS Diluted | 25.78% | -75.69% | |||
| Normalized Diluted EPS | 25.78% | -76.98% | |||
| Average Basic Shares Outstanding | 0.15% | 0.06% | |||
| Average Diluted Shares Outstanding | 0.15% | 0.06% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||